TapImmune Inc. $TPIV is in The #StockGuru Spotlight for Thursday

by | Oct 2, 2014 | Asides

TapImmune Inc. (OTCQB: TPIV) is in The StockGuru Spotlight for Thursday, October 2, 2014.

Prime BOTH sides of the tumor Killing equation

Proprietary peptide antigens used to stimulate a broad based

  • T – Helper cell response (CD4) LONG-LIVED
  • KILLER T-cells to actually KILL the tumor (CD8)

These Proprietary Antigens allow us to treat:

  • Wider patient populations (EG: +50% Vs Roche Herceptin 15%)
  • Multiple Indications
  • Multiple Therapeutic Areas (Cancer and Infectious Disease)

 

 

Most Recent News – Issued Last Month: 

TapImmune Releases Positive Interim Data on Phase I Clinical Trial of Folate Receptor Alpha Antigens in Ovarian and Breast Cancer

All Patients Developed Immune Responses as All Five Peptides Shown to be Immunogenic

SEATTLE, Sep 16, 2014 (BUSINESS WIRE) — TapImmune Inc. (OTCQB:TPIV) is extremely pleased to report that analysis of the interim data from the first 13 patients in a Phase I clinical trial show that each of the patients treated have raised specific T-cell immune responses against a set of 5 naturally processed folate receptor alpha Class II antigenic epitopes. All five of the constituent peptides were found to be immunogenic and all patients developed immune responses to at least one and in most cases more than one of the vaccine peptides.
The trial is fully accrued and as of August 26, 2014, all 22 patients had completed their vaccinations. Eight women with HER2-negative breast cancer, thirteen with ovarian cancer and one with fallopian tube cancer were enrolled. Glynn Wilson, TapImmune’s CEO stated “In general, the vaccine has been well tolerated. This is the first positive endpoint we have reported for the clinical study on folate receptor alpha antigens and when taken together, the promising data on safety and immune responses are tremendously encouraging and provide a clear scientific rationale for progressing to a Phase II Clinical Trial. In addition to the primary Ovarian indication, this set of antigens and our approach fills a significant need for treatments for difficult to treat cancers for which targeted therapies are not available, for example Triple-negative breast cancer.”

The Phase I trial is being carried out at the Mayo Clinic, Rochester, MN. TapImmune has an Exclusive Option to License this antigen technology.